RESUME

I moved to Australia form UK in 2006 after completing my internal medicine training. I then completed training in medical oncology at Monash Health and Western Health before completing fellowship in thoracic malignancies and Head & Neck Cancers at Peter MacCallum Cancer Centre. Subsequently, I completed Doctor of Medicine degree from Monash University where my area of research was bio-marker discovery and cancer stem cells in Breast and Lung Cancers.

I have public appointments at Monash Health, where I am the lead clinician in thoracic, Head & Neck and Melanoma tumour streams. I am also keen researcher and currently investigating several novel therapies as a principal investigator on many clinical trials. I also collaborate with Lab scientist via my association with The Hudson Institute of Medical Research at Monash University.

I am married with 2 kids. I am a keen sportsperson and keep myself fit by playing squash. I also play cricket for Mount Eliza Team.

SPECIAL INTERESTS

Lung, Head & Neck, Skin Cancers/Melanoma, Clinical Trials

 

PUBLIC APPOINTMENTS

Monash Medical Centre, Melbourne, Australia

Peter MacCallum Cancer Centre, Melbourne, Australia

 

HONORARY APPOINTMENTS

Senior Lecturer Monash University, Melbourne, Australia

Clinical Research Associate Hudson Institute of Medical Research, Melbourne, Australia

Medical Oncologist Peninsula Health

 

MY PUBLICATIONS

 

  1. Alamgeer M, Frailty and long-term survival among patients in Australian intensive care units with metastatic cancer: A retrospective registry-based cohort study (FRAIL-CANCER Study). The Lancet Healthy Longevity, 2023
  2. Padhi S, Shrestha P, Alamgeer M et al. Oncology and Intensive Care Doctors’ Perception of Intensive Care Admission of Cancer Patients: A Cross-sectional National Survey. Australian Critical Care, 2023
  3. Ruiyang R, Ueno R, Alamgeer M, et al. Impact of frailty on long-term survival in Australian patients admitted to ICU after elective cancer surgery: A retrospective multicentre cohort study, 2023
  4. Mclean L, Lim A, Bressel M, Lee J, Ladwa R, Guminski A, Hughes B, Bowyer S, Briscoe K, Harris S, Kukard C, Zielinski R, Alamgeer M et al. Immunotherapy for locally advanced and metastatic cutaneous squamous-cell carcinomas in a real-world Australian cohort: Medical Journal of Australia, 2023
  5. Tan S, Spear E, Sane N, Chan J, Nelson A, Alamgeer M et al. Atherosclerotic cardiovascular events in cancer patients treated with immune checkpoint inhibitors: A Retrospective Cohort Study. Heart Lung and Circulation, 2023
  6. Wang Y, Mathai J, Alamgeer M, Parakh S, Paul E, Mitchell P, Arulananda S. Real-world analysis of clinical characteristics and survival outcomes in patients with extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy: Journal of Thoracic Oncology Clin Resp. 2023 Jun 27;4(8) DOI 10.1016/j.jtocrr.2023.100544.
  7. Zaman F, Subramaniam A, Afroz A, Samoon Z, Gough D, Arulananda S, Alamgeer M. Circulating Tumour DNA (ctDNA) as a predictor of clinical outcome in Non-Small Cell Lung Cancer Undergoing Targeted Therapies: A Systematic Review and Meta-analysis. Cancers 2023, 15(9), 2425
  8. Chen J, Guanizo A, Jakasekara S, Inampudi C, Alamgeer M, et al. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor 4 fimepinostat. Journal of Experimental & Clinical Cancer Research 2023
  9. Alamgeer M, Coleman A, McDowell L, Giddings C, Safdar A, Sigston E, Subramaniam A. Treatment Outcomes of Standard (High Dose) Cisplatin and Non-standard Chemotherapy for Locally Advanced Head and Neck Cancer, Cancer Rep 2022 Jul 6;e1674, doi 10.1002/cnr2.1674
  10. Alamgeer M, Subramaniam, A. Estimating the impact of COVID-19-induced coagulopathy. Ann Acad Med Singap, 2021 Apr;50(4):294-296, doi: 10.47102/annals-acadmedsg.2021113
  11. Brokwell N, Alamgeer M, Kumar B, John T, Parker N. Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma, 2020 doi: 10.21037/tlcr-19-485
  12. Lum C, Alamgeer M. Technological and therapeutic advances in small cell lung cancer. Cancers, 2019; 11(10).pii:E1570
  13. Leong T, Gayevskiy V, Steinfort D, Massy M, Marini K, Alamgeer M, et al. Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naïve, metastatic lung cancer. Oncogene, 2018 38(10)1 DOI:10.1038/s41388-018-0536-1
  14. Marini K, Croucher D, McCloy R, Vaghjiani V, Gonzalez-Rajal A, Alamgeer M, et al. Inhibition of activin signalling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. Science Translational Medicine 2018 10(451) DOI: 10.1126/scitranslmed.aat3504
  15. Alamgeer M, Watkins N, Banakh, et al. A phase IIa study of HA-irinotecan, formulation of hyaluronic acidmand irinotecan targeting CD44 in extensive-stage small cell lung cancer. Investigational New Drugs, 2017 DOI: 10.1007/s10637-017-0555-8
  16. Muscat A, popovski D, Jayasekara S, Rossello F, Ferguson M, Marini K, Alamgeer M, et al. Low-Dose histone deacetylase inhibitor treatment leads to tumour growth arrest and multi-lineage differentiation of malignant rhabdoid tumours. Clinical Cancer Research, 2016; DOI: 10.1158/1078-0432.CCR-15-2260
  17. Boolell V, Alamgeer M, Watkins N, Ganju V. The evolution of therapies in Non-small cell lung cancer. Cancers, 2015, 7(3):1815-1846
  18. Alamgeer M, Ganju V, Kumar B, Fox J, Hart S, White M, Harris M, Stuckey J, Prodanovic Z, Schneider-Kolsky MS, Watkins DN. Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research, 2014 16 (2).R44
  19. Alamgeer M, Ganju V, Szczepny A, Russell PA, Prodanovic P, Kumar B, Wainer Z, Brown TJ, Schneider-Kolsky M, Conron M, Wright G, Watkins DN. The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 in early stage non-small cell lung cancer. Thorax, 2013; 68:1095-1104
  20. Leong TL, Marini KD, Rossello FJ, Jayasekara SN, Russell PA, Prodanovic Z, Kumar B, Ganju V, Alamgeer M, Irving LB, Steinfort DP, Peacock CD, Cain JE, Szczepny A, Watkins DN: Genomic characterisation of small cell lung cancer patient-derived xenograft generated from endobronchial ultrasound guided transbronchial needle aspiration specimens. PLOS One, 2014; 9 e0106862.
  21. Alamgeer M, Peacock C,Matsui W, Ganju V, Watkins DN: Cancer stem cells in lung cancer, evidence and controversies. Respirology, 2013; 18: 757-64.
  22. Sweet Ng, David S, Alamgeer M, Ganju V: Impact of Pretreatment Combined 18 F- Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer. International Journal of Radiation Oncology Biology and Physics, 2015; 93: 111-117.
  23. Alamgeer M, Ganju V, Watkins DN: Novel therapeutic targets in NSCLC. Current opinion in pharmacology. 2013 Jun;13(3):394-401.
  24. Alamgeer M, Rogers T, Fox SB, Solomon B: Crizotinib for the treatment of non-small cell lung cancer with ALK gene rearrangements. Clinical Investigation 2012 2:9,895- 907.
  25. Neeman J, Tan S, Alamgeer M. Cardiovascular Risk Factor Screening in Patients receiving Immune Checkpoint Inhibitors. (In Preparation- Ethics approved, data collection in process.
  26. Effect of Protocol-Based ICU admission – Results from Australia-wide Cross-Sectional National Survey (data collected- manuscript in preparation)
  27. Pre and Post COVID Pandemic Outcomes of Cancer Patients admitted to the Hospital between 2018 and 2022 – ANZICS Registry Data. (In preparation)
  28. Outcomes of Cancer Patients, utilizing Victorian Admitted Episode Dataset (VAED), Victoria Death Index (VDI) and Victorian Cancer Registry Dataset (VCR) – A multi- collaborative project (Planned to start late 2024)
  29. Alamgeer M, Kumar B, Fox J, Marini K, Rossello F, Watkis DN, Ganju V: The effect of chemotherapeutic drugs on breast cancer stem cells identified by aldehyde dehydrogenase 1 (ALDH1) using serial tumour specimens. Asia-Pac J Clin Oncol 2013; 9 (Suppl.2): 49-50
  30. Alamgeer M, Brown TJ, Midol P, Markman B, Briggs P, Marini K, Watkins DN, Ganju V: A phase IIa study of HA-irinotecan, a formulation of hyaluronic acid and irinotecan, in the treatment of extensive stage small cell lung cancer and its effect on cancer stem-like cells. 15 th International World Lung Cancer Conference, Sydney, Australia 2013
  31. Alamgeer M, Brown TJ, Kumar B, Wright G, Russell P, Conron M, Wainer Z, Ganju V: Evaluation of the relationship of Cancer Stem Cell markers and the risk of recurrence in Non Small Cell Lung Cancer. 14 th International World Lung Cancer Conference , Amsterdam, Netherlands: 2011, Oral abstract no. O15.01
  32. Alamgeer M, Szczepny A, Kumar B, Watkins DN, Wright G, Prodanovic Z, Ganju V: the prognostic significance of ALDEHYDE DEHYDROGENASE 1 (ALDH1) and CD133 n early-stage NSCLC. Lorne Cancer conference 2013, Lorne, Australia
  33. Ng SP, David S, Alamgeer M, Ganju V: Impact of pretreatment combined 18F- fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography staging on radiotherapy treatment decisions in locally advanced breast cancer: a prospective evaluation. Accepted for oral presentation at American Society for Radiation Oncology annual scientific meeting, San Francisco, 2014
  34. Alamgeer M, White M, Stuckey J, Harris, M, Ganju V: Prediction of axillary lymph node response to neoadjuvant chemotherapy (NAC) by changes in maximum standard uptake values (SUVmax) with 18 FDG-PET (PET) imaging of the primary breast tumour: Submitted to European Society of Medical Oncology (ESMO) annual scientific meeting 2014
  35. Alamgeer M, Pick A, Ramdave et al. Investigating Phenotypic and Genomic Heterogeneity in Malignant Pleural Mesothelioma: JTO Jan 2017
  36. Alamgeer M, Briggs P, Markman B, et al. Updated Analysis of Phase II Study of HA- Irinotecan, a CD44-Targeting Formulation of Hyaluronic Acid and Irinotecan, in Small Cell Lung Cancer: Topic: Drug Treatment Alone and in Combination with Radiotherapy: JTO Jan 2017
  37. Menon S, Alamgeer M. Incidence of Unplanned Admissions During Chemotherapy for Head and Neck and Lung Cancers. Asia-Pacific Journal of Clinical Oncology 13, 131-131 (2017)
  38. Muttiah C, Alamgeer M. Retrospective Analysis of Thoracic Oncology at Monash Health 2016-2017 Specifically Investigating Prevalence of EGFR Mutated Lung Cancers. Aisa-Pacific Journal of Clinical Oncology 13, 162-162 (2017)
  39. Marshall L, Giddings C, Coleman A, Silvers MA, Alamgeer M. Head and Neck Cancers Audit of Chemotherapy at Monash Cancer Centre. Asia-Pacific Journal of Clinical Oncology 13, 186-186 (2017)
  40. Treatment outcomes in malignant pleural mesothelioma: A single center experience of systemic therapies and biomarkers. Balasubramanian A, Pick A, Kumar B, Prodanovic Z, Joshi P, Alamgeer M. Journal of Clinical Oncology, Volume 37, Issue S15
  41. Balasubramanian A, Pick A, Kumar B, Prodanovic Z, Joshi P, Alamgeer M. Journal of Clinical Oncology, 2019 37(15-suppl):e20070-e20070.
  42. CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma. 2021. Journmal of ImmunoTherapy of Cancer 9 (Suppl2)
  43. Prevalence of sleep disturbance in newly diagnosed lung cancer and impacts of Chemotherapy: A systematic review. Clinical Oncology Society of Australia 2021
  44. Davies A, Menon S, Alamgeer M. Outcomes in NSCLC patients with early termination of immune checkpoint inhibitors due to toxicities. Journal of Thoracic Oncology 16 (3), S245.
  45. Alamgeer M, White M, Stuckey J, Harris, M, Ganju V. Prediction of Axillary Lymph Node Response to Neoadjuvant Chemotherapy (Nac) By Changes in Maximum Standard Uptake Values (Suvmax) with 18Fdg-PET (Pet) Imaging of the Primary Breast Tumour. Annals of Oncology 2014 https://doi.org/10.1093/annonc/mdu328.1
  46. Haydon A, Alamgeer M, Brungs D, Collichio F.CERPASS,as open lablelled, phase II study of Cem

 

PROFESSIONAL MEMBERSHIPS

  1. American Society of Clinical Oncology
  2. International Association of Study in Lung Cancer
  3. Medical Oncology Group of Australia
  4. Australasian Lung Cancer Trial Group
  5. Australian Gastro-Intestinal Trials Group
  6. International Mesothelioma Interest Group
  7. Australasian Sarcoma Study Group
  8. Member of RACP Somatic Cancer Advisory Committee
  9. Member eviQ Respiratory Medical Oncology Reference Committee EVIQ committee (Cancer Institute New South Wales)

GRANTS & OTHER AWARDS

  1. Peninsula and Southeast Oncology Research Grant   2022
  2. Cancer Council Victoria “Grant in Aid” 2021
  3. Slater and Gordon Health Projects and Research Grant 2016
  4. Monash Senior Medical Staff Association Emerging Investigator Research Award 2016
  5. ‘Rising Star Researcher of 2015’ awarded by MHTP
  6. Monash Comprehensive Cancer Care research grant 2013
  7. Merit scholarships and awards (University of Peshawar)